ArticleBMC veterinary research2025
Effects of ascorbic acid and cysteine supplementation on preimplantation embryo development and oxidative stress-related gene expression in dromedary camels.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxidative stress (OS) is a harmful threat during early preimplantation that compromises embryonic development. Ascorbic acid and cysteine were found to have significant contributions in various physiological processes, including embryonic development and mitigating various stressors, by acting as antioxidants and regulating gene expression. This study evaluated the mitigating impact of ascorbic acid and cysteine addition on OS during in vitro culture (IVC) and subsequent early embryonic developmental stages of the dromedary camel. The ovaries were sourced from a nearby slaughterhouse; only high-quality oocytes were used for in vitro embryo production (IVP). Produced zygotes were in vitro cultured with ascorbic acid, cysteine, or both under a high oxygen level (20%). This study included four experimental groups: an untreated group without antioxidant i.e., control (T1), the 2nd group supplemented with 150 µg/mL ascorbic acid (T2), the 3rd group supplemented with 100 µM cysteine (T3), and the 4th group (T4) enriched with a combination of both antioxidants (150 µg/mL ascorbic acid and 100 µM cysteine). Embryo development was monitored throughout different preimplantation stages. Real-time PCR was used to assess the relative abundance of various genes, including genes that are related to oxidative stress (catalase (CAT), superoxide dismutase (SOD), and thioredoxin (TXN)), apoptosis related genes (B-cell lymphoma 2 (BCL2), and tumor suppressor protein (p53)), and metabolic related gene (glucose transporter 1 (GLUT-1)).
resultsThe results indicated an increased cleavage rate (P < 0.05) in T2 (29.41%), T3 (32.77%), and T4 (27.16%) compared to T1 (14.05%). Moreover, the rate of blastocyst formation was increased (P < 0.05) in T2 (24.79%), T3 (21.43%), and T4 (18.52%), compared to T1 (2.89%). However, the rates of blocked embryos at the morula stage were 8.68%, 4.62%, 10.08%, and 8.23% in T1, T2, T3, and T4, respectively. The expression of genes regulating the antioxidant response (CAT, SOD1, and TXN), anti-apoptosis (BCL2), and metabolic activity (GLUT1) was upregulated in the treated groups.
conclusionsTo conclude, the findings of this study clearly illustrate increased cleavage and blastocyst rates with supplementation of ascorbic acid, cysteine, or a combination of both. Furthermore, gene expression data support the positive effects of antioxidant supplementation to IVC media on enhancing embryonic development by promoting the intracellular defense mechanism and inhibition of apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.